OptiNose Inc (OPTN)
0.878
-0.03
(-3.34%)
USD |
NASDAQ |
May 02, 15:12
OptiNose Cash from Financing (TTM): 0.30M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 0.30M |
September 30, 2023 | 51.08M |
June 30, 2023 | 51.32M |
March 31, 2023 | 51.35M |
December 31, 2022 | 51.44M |
September 30, 2022 | 43.66M |
June 30, 2022 | 43.32M |
March 31, 2022 | 43.64M |
December 31, 2021 | 43.32M |
September 30, 2021 | 20.62M |
June 30, 2021 | 54.14M |
March 31, 2021 | 54.36M |
December 31, 2020 | 83.81M |
Date | Value |
---|---|
September 30, 2020 | 103.33M |
June 30, 2020 | 66.50M |
March 31, 2020 | 66.72M |
December 31, 2019 | 37.53M |
September 30, 2019 | -2.385M |
June 30, 2019 | 2.083M |
March 31, 2019 | 61.46M |
December 31, 2018 | 59.58M |
September 30, 2018 | 260.07M |
June 30, 2018 | 258.17M |
March 31, 2018 | 199.62M |
December 31, 2017 | 236.12M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-2.385M
Minimum
Sep 2019
103.33M
Maximum
Sep 2020
45.59M
Average
51.08M
Median
Sep 2023
Cash from Financing (TTM) Benchmarks
Madrigal Pharmaceuticals Inc | 595.12M |
Viking Therapeutics Inc | 873.23M |
Zevra Therapeutics Inc | 28.46M |
Spero Therapeutics Inc | 0.221M |
Karuna Therapeutics Inc (DELISTED) | 483.37M |